DELL'ORO, RAFFAELLA
 Distribuzione geografica
Continente #
NA - Nord America 15.191
AS - Asia 10.073
EU - Europa 6.567
SA - Sud America 1.446
AF - Africa 252
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 9
Totale 33.563
Nazione #
US - Stati Uniti d'America 14.357
SG - Singapore 3.617
CN - Cina 2.075
VN - Vietnam 1.608
HK - Hong Kong 1.279
RU - Federazione Russa 1.198
IT - Italia 1.193
BR - Brasile 1.121
DE - Germania 926
SE - Svezia 864
CA - Canada 711
IE - Irlanda 641
UA - Ucraina 402
GB - Regno Unito 345
FR - Francia 315
IN - India 283
BD - Bangladesh 242
KR - Corea 207
FI - Finlandia 175
AT - Austria 123
AR - Argentina 110
IQ - Iraq 109
ID - Indonesia 92
TR - Turchia 87
ZA - Sudafrica 86
PK - Pakistan 74
MX - Messico 72
PL - Polonia 62
JP - Giappone 61
NL - Olanda 61
SA - Arabia Saudita 54
EC - Ecuador 52
PH - Filippine 49
ES - Italia 46
CO - Colombia 44
UZ - Uzbekistan 43
VE - Venezuela 42
DK - Danimarca 40
KE - Kenya 31
BE - Belgio 29
MY - Malesia 29
TN - Tunisia 26
AU - Australia 25
CL - Cile 25
MA - Marocco 23
PY - Paraguay 21
CZ - Repubblica Ceca 20
EG - Egitto 20
JO - Giordania 19
AE - Emirati Arabi Uniti 16
ET - Etiopia 16
PE - Perù 15
BG - Bulgaria 14
CH - Svizzera 14
LT - Lituania 14
RO - Romania 14
AZ - Azerbaigian 12
AL - Albania 10
IR - Iran 10
KZ - Kazakistan 10
LB - Libano 10
DZ - Algeria 9
LK - Sri Lanka 9
PS - Palestinian Territory 9
BY - Bielorussia 8
EE - Estonia 8
HN - Honduras 8
IL - Israele 8
JM - Giamaica 8
PT - Portogallo 8
TH - Thailandia 8
UY - Uruguay 8
CI - Costa d'Avorio 7
DO - Repubblica Dominicana 7
EU - Europa 7
NP - Nepal 7
OM - Oman 7
BH - Bahrain 6
BO - Bolivia 6
CR - Costa Rica 6
PA - Panama 6
QA - Qatar 6
RS - Serbia 6
SN - Senegal 6
AO - Angola 5
HR - Croazia 5
HU - Ungheria 5
NI - Nicaragua 5
TW - Taiwan 5
BA - Bosnia-Erzegovina 4
GR - Grecia 4
NG - Nigeria 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BB - Barbados 3
GE - Georgia 3
KG - Kirghizistan 3
MG - Madagascar 3
MK - Macedonia 3
MU - Mauritius 3
Totale 33.519
Città #
Singapore 2.013
Ann Arbor 1.870
Ashburn 1.382
Hong Kong 1.256
San Jose 994
Fairfield 898
Woodbridge 884
Houston 628
Dublin 614
Chandler 587
Frankfurt am Main 569
Toronto 539
Wilmington 470
Ho Chi Minh City 440
New York 409
Hanoi 407
Hefei 405
Jacksonville 405
Seattle 355
Dallas 335
Beijing 317
Milan 285
Chicago 277
Santa Clara 271
Dearborn 268
Los Angeles 260
Cambridge 235
Princeton 210
Seoul 201
The Dalles 201
Boardman 146
Lauterbourg 138
Moscow 128
Nanjing 108
São Paulo 105
Lawrence 104
Buffalo 103
Shanghai 103
Vienna 102
Council Bluffs 98
Altamura 94
Da Nang 85
Munich 73
Helsinki 66
Orem 65
Lachine 63
Haiphong 62
San Diego 58
Jakarta 57
London 56
Guangzhou 53
Chennai 51
Rome 51
Baghdad 49
Atlanta 46
Lissone 46
Rio de Janeiro 42
Warsaw 42
Nanchang 41
Dong Ket 40
Montreal 38
Brooklyn 37
Johannesburg 36
Tashkent 36
Tokyo 36
Changsha 35
Andover 32
San Francisco 32
Turku 32
Düsseldorf 31
Shenyang 31
Denver 30
Hebei 30
Nuremberg 30
Belo Horizonte 28
Salt Lake City 28
Tianjin 28
Dhaka 27
Mumbai 27
Columbus 25
Fremont 25
Brussels 24
Falls Church 24
Hải Dương 24
Phoenix 23
Hangzhou 22
Zhengzhou 22
Ha Long 21
Jiaxing 21
Jinan 21
Kunming 21
Poplar 21
Riyadh 21
Can Tho 20
Lahore 19
Monza 19
Nairobi 19
New Delhi 19
Norwalk 19
Ottawa 19
Totale 21.313
Nome #
Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia 485
Baroreceptors as a target of device-based neuromodulation in heart failure: Long-term outcomes 459
Contrasting effects of carotid baroreceptor stimulation on regional sympathetic drive in chronic human heart failure 446
Heart rate as a sympathetic marker during acute adrenergic challenge 433
Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. 346
Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values 333
Sympathetic Neural Overdrive in the Obese and Overweight State: Meta-Analysis of Published Studies 332
Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. 323
Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: A microneurographic study 316
Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: Characteristics and mechanisms 312
Neurogenic abnormalities in masked hypertension 303
Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea 303
Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis 299
Severe systemic cytomegalovirus infection in an immunocompetent patient outside the intensive care unit: a case report 294
Prevalence of cardiovascular risk factors in an unselected Italian population. Results of the CardioLab Project 2004-2008 292
It is never too late for a genetic disease: a case of a 79-year-old man with persistent hypokalemia 291
Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome 288
Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients 288
Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states 288
Structural alterations of the retinal microcirculation in the "prehypertensive" high-normal blood pressure state 286
Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state 284
Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies 282
Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child a cirrhosis 278
Extreme dipping: Always means nocturnal hypotension? 274
Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity 273
Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives 273
Threshold and Target for Blood Pressure Lowering in the Elderly 273
Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease 272
Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity 269
Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure 268
Role of ambulatory blood pressure monitoring in resistant hypertension 268
Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study 264
DIFFERING EFFECTS OF RENAL DENERVATION ON BLOOD PRESSURE AND SYMPATHETIC NERVE TRAFFIC: A SYSTEMATIC REVIEW AND META-ANALYSIS 263
Relationship among morning blood pressure surge, 24-hour blood pressure variability, and cardiovascular outcomes in a white population 263
Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years 263
Adrenergic and reflex abnormalities in obesity-related hypertension 256
Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly 255
Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients 255
Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study 254
IMPACT OF SEASONAL BLOOD PRESSURE CHANGES ON VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY 252
Multicentre randomised, double blind, evaluation of nebivolol plus HCTZ and irbesartan plus HCTZ in the treatment of systolic hypertension in the elderly: the NEHIS Study 250
Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension 249
Effects of hypertension and obesity on the sympathetic activation of heart failure patients 248
Different neuroadrenergic activation and baroreflex function in resistant and pseudoresistant hypertension: a microneurographic study 246
Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction 245
Cardiovascular risk and adrenergic overdrive in the metabolic syndrome 242
Diurnal blood pressure variation and sympathetic activity 242
SYMPATHETIC OVERDRIVE IN THE RESISTANT HYPERTENSIVE PHENOTYPE 238
Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality 237
Response to possible difference in the sympathetic activation on extreme dippers with or without exaggerated morining surge 236
FAILURE OF ANTIHYPERTENSIVE TREATMENT TO RESTORE NORMAL SYMPATHETIC ACTIVITY 234
Effects of acute carotid baroreceptor stimulation on sympathetic nerve traffic in resistant and uncontrolled hypertension: a systematic review and meta-analysis 233
Early sympathetic activation in the initial clinical stages of chronic renal failure 233
Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications 233
Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis 233
Triglyceride-glucose Index and Mortality in a Large Regional-based Italian Database (Urrah Project) 231
Predictive value of different indices of blood pressure variability on 230
Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension 230
Sympathetic nerve traffic, insulin resistance and baroreflex control of circulation in patients with resistant hypertension 229
Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation 225
Comparison of electrocardiographic versus echocardiographic detection of left ventricular mass changes over time and evaluation of new onset left ventricular hypertrophy 221
New onset left atrial dilatation in the general population: A quarter-century follow-up 220
Reduced Insulin Sensitivity is Associated with Adrenergic Overdrive Independently on Obesity and Hypertension 220
Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report 220
Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials 216
Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation 216
Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings 214
Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity 213
Association Between Arterial Stiffness, High Blood Pressure, and Hypertensive Phenotypes: Insights from the PAMELA Study 212
The "J curve" problem revisited: old and new findings 212
Long-term increase in serum uric acid and its predictors over a 25 year follow-up: Results of the PAMELA study 211
Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis 211
Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives 206
Clinical correlates and subclinical cardiac organ damage in different extreme dipping patterns 206
Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project 205
Left ventricular hypertrophy in isolated and dual masked hypertension 203
Comparison between visit-to-visit office and 24-h blood pressure variability in treated hypertensive patients 203
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study 199
Prevalence, Awareness And Treatment Of Cardiovascular Risk Factors In Health Professionals In The Cardiovascular Field: The Protecto Esh-Siia Study 198
Salt intake and sympathetic activity - Response 198
White-Coat Hypertension Without Organ Damage: Impact on Long-Term Mortality, New Hypertension, and New Organ Damage 198
Habitual Regular Coffee Consumption And Arterial Stiffness -Data From The 3rd Pamela Survey 197
Sympathetic activation in congestive heart failure: Evidence, consequences and therapeutic implications 196
Reduced insulin sensitivity is associated with adrenergic overdrive in hemochromatosis independently on obesity and hypertension 196
Response to sympathetic activity, heart failure, obesity, and metabolic syndrome: Is there any role for obstructive sleep apnea? 195
Baroreflex activation therapy systems: current status and future prospects 195
High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid 194
Diagnostic and Therapeutic Approach to Different Hypertensive Phenotypes According to the 2023 ESH Guidelines 193
How to assess sympathetic nervous system activity in clinical practice 193
Sympathetic activation in obesity: a noninnocent bystander 192
Essential hypertension and the sympathetic nervous system 191
Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias 191
Serum Uric Acid, Hypertriglyceridemia, and Carotid Plaques: A Sub-Analysis of the URic Acid Right for Heart Health (URRAH) Study 190
Prognostic Value and Relative Cutoffs of Triglycerides Predicting Cardiovascular Outcome in a Large Regional‐Based Italian Database 190
The neglected role of the electrocardiogram in the diagnostic work-up of hypertensive patients: a study in clinical practice 190
Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement 190
Cardio-Ankle Vascular Index As A Marker Of Left Ventricular Hypertrophy In Treated Hypertensives: Findings From The Pamela Study 188
Prognosti relevance of electrocardiographic tp-te interval in the general and in the hypertensive population: data from the pamela study 186
COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? 186
The PAMELA research project: a 25-year long journey 186
Totale 24.841
Categoria #
all - tutte 114.583
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.583


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021192 0 0 0 0 0 0 0 0 0 0 0 192
2021/20221.700 147 125 235 183 138 128 71 68 95 110 163 237
2022/20232.510 270 708 231 253 150 408 41 155 140 34 80 40
2023/20242.062 51 54 89 112 285 491 388 61 224 39 41 227
2024/20255.787 329 665 231 251 467 161 288 280 536 852 710 1.017
2025/202614.075 1.888 1.086 1.158 1.564 1.445 690 1.941 604 1.026 1.191 988 494
Totale 34.155